ArticleNature communications2024
Multi-parametric thrombus profiling microfluidics detects intensified biomechanical thrombogenesis associated with hypertension and aging.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Protein-protein interaction disruption as a next-generation antithrombotic strategy.Journal of thrombosis and thrombolysis · 2026Review
- Complementary targeted constructs factor XI/XIa inhibition.Blood advances · 2026Article
- From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.Current opinion in hematology · 2026Review
- Dark-Pi Imaging System Permits Open-Source Label-Free Microfluidic Monitoring of Platelet Aggregation by Cellular Light Scattering.Sensors (Basel, Switzerland) · 2026Article
- Ginsenoside Rg1 attenuates platelet activation under shear stress via multi-target suppression of PI3K/AKT and ERK1/2 pathways: an in vitro microfluidic study.Journal of thrombosis and thrombolysis · 2026Article
- Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanobiology of cancer-associated thrombosis: from molecular mechanisms to therapeutic innovation.Journal of nanobiotechnology · 2026Review
- Cocklebur-inspired magnetic nanomotors for targeted thrombus therapy.Bioactive materials · 2026Article
- Vorticity-Facilitated Platelet Aggregation: a High Expansion-Ratio Stenotic Microfluidic Platform Unravels the Role of Complex Flow Dynamics in Arterial Thrombosis.Advanced healthcare materials · 2025Article
- Applications of microfluidic chip technology in microvascular thrombosis research.Mikrochimica acta · 2025Review
- In situ protein corona-camouflaged supramolecular assemblies remodel thrombotic microenvironment for improved arterial homeostasis.Science advances · 2025Article
- Comparing machine learning models for predicting preoperative DVT incidence in elderly hypertensive patients with hip fractures: a retrospective analysis.Scientific reports · 2025Article
- Fragmented thrombi, targeted solutions: Exploring GPVI inhibition in high-shear environments.Biophysical journal · 2025Article
Corrections and comments
- Update of
Authors and funding
23 authors.
Funding
Abstract
Arterial thrombosis is a leading cause of death and disability worldwide with no effective bioassay for clinical prediction. As a symbolic feature of arterial thrombosis, severe stenosis in the blood vessel creates a high-shear, high-gradient flow environment that facilitates platelet aggregation towards vessel occlusion. Here, we present a thrombus profiling assay that monitors the multi-dimensional attributes of thrombi forming in such biomechanical conditions. Using this assay, we demonstrate that different receptor-ligand interactions contribute distinctively to the composition and activation status of the thrombus. Our investigation into hypertensive and older individuals reveals intensified biomechanical thrombogenesis and multi-dimensional thrombus profile abnormalities, endorsing the diagnostic potential of the assay. Furthermore, we identify the hyperactivity of GPIbα-integrin α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.